Christopher V Plowe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11342311/publications.pdf

Version: 2024-02-01

181 papers 16,959 citations

60 h-index 124 g-index

186 all docs

186 docs citations

186 times ranked 10280 citing authors

#	Article	IF	Citations
1	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
2	A Molecular Marker for Chloroquine-Resistant Falciparum Malaria. New England Journal of Medicine, 2001, 344, 257-263.	27.0	873
3	Pyrimethamine and Proguanil Resistance-Conferring Mutations in Plasmodium falciparum Dihydrofolate Reductase: Polymerase Chain Reaction Methods for Surveillance in Africa. American Journal of Tropical Medicine and Hygiene, 1995, 52, 565-568.	1.4	577
4	A Research Agenda to Underpin Malaria Eradication. PLoS Medicine, 2011, 8, e1000406.	8.4	565
5	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515
6	Reemergence of Chloroquineâ€SensitivePlasmodium falciparumMalaria after Cessation of Chloroquine Use in Malawi. Journal of Infectious Diseases, 2003, 187, 1870-1875.	4.0	453
7	Molecular Markers for Failure of Sulfadoxineâ€Pyrimethamine and Chlorproguanilâ€Dapsone Treatment ofPlasmodium falciparumMalaria. Journal of Infectious Diseases, 2002, 185, 380-388.	4.0	452
8	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
9	Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 2013, 45, 648-655.	21.4	424
10	Mechanisms of Resistance of Malaria Parasites to Antifolates. Pharmacological Reviews, 2005, 57, 117-145.	16.0	400
11	Return of Chloroquine Antimalarial Efficacy in Malawi. New England Journal of Medicine, 2006, 355, 1959-1966.	27.0	369
12	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	4.0	368
13	Genome-wide and fine-resolution association analysis of malaria in West Africa. Nature Genetics, 2009, 41, 657-665.	21.4	345
14	Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology, 2001, 17, 582-588.	3.3	329
15	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nature Medicine, 2016, 22, 614-623.	30.7	313
16	A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine, 2011, 365, 1004-1013.	27.0	311
17	Development of a metabolically active, non-replicating sporozoite vaccine to prevent <i>Plasmodium falciparum</i> malaria. Hum Vaccin, 2010, 6, 97-106.	2.4	258
18	Blood group O protects against severe <i>Plasmodium falciparum</i> malaria through the mechanism of reduced rosetting. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17471-17476.	7.1	251

#	Article	IF	CITATIONS
19	Genetic loci associated with delayed clearance of <i>Plasmodium falciparum</i> following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 240-245.	7.1	242
20	The Threat of Artemisinin-Resistant Malaria. New England Journal of Medicine, 2011, 365, 1073-1075.	27.0	232
21	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	1.4	204
22	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2711-2716.	7.1	201
23	Differential var gene transcription in Plasmodium falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Molecular and Biochemical Parasitology, 2006, 150, 211-218.	1.1	180
24	Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine, 2005, 23, 2243-2250.	3.8	174
25	Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood, 2000, 96, 2358-2363.	1.4	169
26	Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet, The, 2001, 358, 890-891.	13.7	164
27	Origin and Dissemination ofPlasmodium falciparumDrugâ€Resistance Mutations in South America. Journal of Infectious Diseases, 2002, 186, 999-1006.	4.0	163
28	CLEARANCE OF DRUG-RESISTANT PARASITES AS A MODEL FOR PROTECTIVE IMMUNITY IN PLASMODIUM FALCIPARUM MALARIA. American Journal of Tropical Medicine and Hygiene, 2003, 69, 558-563.	1.4	159
29	Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development. Science Translational Medicine, 2009, 1, 2ra5.	12.4	154
30	Community Permission for Medical Research in Developing Countries. Clinical Infectious Diseases, 2005, 41, 255-259.	5.8	148
31	Artemisinin-Resistant Malaria: Research Challenges, Opportunities, and Public Health Implications. American Journal of Tropical Medicine and Hygiene, 2012, 87, 231-241.	1.4	136
32	Return of Chloroquineâ€Susceptible Falciparum Malaria in Malawi Was a Reexpansion of Diverse Susceptible Parasites. Journal of Infectious Diseases, 2010, 202, 801-808.	4.0	126
33	Plasmodium falciparum crossresistance between trimethoprim and pyrimethamine. Lancet, The, 2001, 358, 1066-1067.	13.7	125
34	A Single Mutation in K13 Predominates in Southern China and Is Associated With Delayed Clearance of <i>Plasmodium falciparum </i> Following Artemisinin Treatment. Journal of Infectious Diseases, 2015, 212, 1629-1635.	4.0	125
35	P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resistance Updates, 1998, 1, 389-396.	14.4	120
36	Impact of Trimethoprim‧ulfamethoxazole Prophylaxis on Falciparum Malaria Infection and Disease. Journal of Infectious Diseases, 2005, 192, 1823-1829.	4.0	119

#	Article	IF	CITATIONS
37	ASSOCIATION OF SCHISTOSOMA HAEMATOBIUM INFECTION WITH PROTECTION AGAINST ACUTE PLASMODIUM FALCIPARUM MALARIA IN MALIAN CHILDREN. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1124-1130.	1.4	118
38	The evolution of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, S11-S14.	1.8	109
39	Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2008, 3, e1465.	2.5	104
40	ASSOCIATION OF INTRALEUKOCYTIC PLASMODIUM FALCIPARUM MALARIA PIGMENT WITH DISEASE SEVERITY, CLINICAL MANIFESTATIONS, AND PROGNOSIS IN SEVERE MALARIA. American Journal of Tropical Medicine and Hygiene, 2003, 69, 253-259.	1.4	103
41	Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. Journal of Infectious Diseases, 2017, 216, 468-476.	4.0	102
42	World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal, 2007, 6, 121.	2.3	99
43	Monitoring antimalarial drug resistance: making the most of the tools at hand. Journal of Experimental Biology, 2003, 206, 3745-3752.	1.7	95
44	Impact of HIVâ€Associated Immunosuppression on Malaria Infection and Disease in Malawi. Journal of Infectious Diseases, 2006, 193, 872-878.	4.0	95
45	Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali. PLoS Medicine, 2007, 4, e93.	8.4	94
46	High Levels of Plasmodium falciparum Rosetting in All Clinical Forms of Severe Malaria in African Children. American Journal of Tropical Medicine and Hygiene, 2009, 81, 987-993.	1.4	94
47	Molecular assays for surveillance of antifolate-resistant malaria. Lancet, The, 1998, 351, 1629-1630.	13.7	93
48	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1202-1206.	1.4	89
49	Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2003, 69, 558-63.	1.4	89
50	Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Molecular and Biochemical Parasitology, 1998, 94, 205-214.	1.1	87
51	Determinants of Treatment Response to Sulfadoxine-Pyrimethamine and Subsequent Transmission Potential in Falciparum Malaria. American Journal of Epidemiology, 2002, 156, 230-238.	3.4	83
52	Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study. BMJ: British Medical Journal, 2004, 328, 545.	2.3	81
53	Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Malaria Journal, 2012, 11, 41.	2.3	79
54	Return of Widespread Chloroquine-Sensitive Plasmodium falciparum to Malawi. Journal of Infectious Diseases, 2014, 210, 1110-1114.	4.0	79

#	Article	IF	CITATIONS
55	Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1124-30.	1.4	75
56	Limited Geographical Origin and Global Spread of Sulfadoxine-Resistant dhps Alleles in Plasmodium falciparum Populations. Journal of Infectious Diseases, 2011, 204, 1980-1988.	4.0	74
57	Community Pyrimethamine-Sulfadoxine Use and Prevalence of Resistant Plasmodium falciparum Genotypes in Mali: A Model for Deterring Resistance. American Journal of Tropical Medicine and Hygiene, 1996, 55, 467-471.	1.4	68
58	Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. Journal of Infectious Diseases, 2013, 207, 511-519.	4.0	66
59	Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali American Journal of Tropical Medicine and Hygiene, 2002, 67, 604-610.	1.4	66
60	Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial. PLOS Clinical Trials, 2006, 1, e34.	3.5	64
61	Effects of Concomitant Schistosoma haematobium Infection on the Serum Cytokine Levels Elicited by Acute Plasmodium falciparum Malaria Infection in Malian Children. Infection and Immunity, 2006, 74, 5718-5724.	2.2	62
62	Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malaria Journal, 2010, 9, 175.	2.3	61
63	Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Medicine, 2020, 12, 6.	8.2	61
64	Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resistance Updates, 2004, 7, 279-288.	14.4	58
65	No Evidence of Delayed Parasite Clearance after Oral Artesunate Treatment of Uncomplicated Falciparum Malaria in Mali. American Journal of Tropical Medicine and Hygiene, 2012, 87, 23-28.	1.4	58
66	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal, 2007, 6, 119.	2.3	57
67	The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication of Malaria. Journal of Infectious Diseases, 2009, 200, 1646-1649.	4.0	57
68	Monitoring and Deterring Drug-Resistant Malaria in the Era of Combination Therapy. American Journal of Tropical Medicine and Hygiene, 2007, 77, 160-169.	1.4	57
69	Association of intraleukocytic Plasmodium falciparum malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. American Journal of Tropical Medicine and Hygiene, 2003, 69, 253-9.	1.4	57
70	A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-densityÂPlasmodium falciparum and Plasmodium vivaxÂinfections. Malaria Journal, 2017, 16, 377.	2.3	56
71	Designing malaria vaccines to circumvent antigen variability. Vaccine, 2015, 33, 7506-7512.	3.8	54
72	Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE, 2010, 5, e9041.	2.5	54

#	Article	IF	Citations
73	Molecular Diagnosis of Resistance to Antimalarial Drugs during Epidemics and in War Zones. Journal of Infectious Diseases, 2004, 190, 853-855.	4.0	52
74	Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 744-752.	1.4	52
75	An ultrasensitive reverse transcription polymerase chain reaction assay to detect asymptomatic low-density Plasmodium falciparum and Plasmodium vivax infections in small volume blood samples. Malaria Journal, 2015, 14, 520.	2.3	51
76	Vaccines for Malaria: How Close Are We?. Annual Review of Medicine, 2012, 63, 345-357.	12.2	50
77	Stable malaria incidence despite scaling up control strategies in a malaria vaccine-testing site in Mali. Malaria Journal, 2014, 13, 374.	2.3	47
78	A network to monitor antimalarial drug resistance: a plan for moving forward. Trends in Parasitology, 2008, 24, 43-48.	3.3	46
79	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	12.8	46
80	Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malaria Journal, 2022, 21, 104.	2.3	46
81	Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine, 2004, 22, 3169-3174.	3.8	45
82	World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malaria Journal, 2007, 6, 122.	2.3	45
83	LOW MULTIPLICATION RATES OF AFRICAN PLASMODIUM FALCIPARUM ISOLATES AND LACK OF ASSOCIATION OF MULTIPLICATION RATE AND RED BLOOD CELL SELECTIVITY WITH MALARIA VIRULENCE. American Journal of Tropical Medicine and Hygiene, 2006, 74, 554-563.	1.4	45
84	Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. Current Opinion in Microbiology, 2001, 4, 415-420.	5.1	44
85	Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. Malaria Journal, 2013, 12, 82.	2.3	44
86	Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS ONE, 2010, 5, e13490.	2.5	42
87	Monitoring and deterring drug-resistant malaria in the era of combination therapy. American Journal of Tropical Medicine and Hygiene, 2007, 77, 160-9.	1.4	42
88	A bifunctional dihydrofolate synthetase–folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. Molecular and Biochemical Parasitology, 2001, 112, 239-252.	1.1	41
89	Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1466-1476.	1.4	41
90	Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar American Journal of Tropical Medicine and Hygiene, 2002, 67, 400-405.	1.4	39

#	Article	IF	CITATIONS
91	A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 626-31.	2.1	39
92	Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial. PLoS ONE, 2013, 8, e79323.	2.5	38
93	The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malaria Journal, 2007, 6, 118.	2.3	37
94	Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. American Journal of Tropical Medicine and Hygiene, 2006, 74, 554-63.	1.4	37
95	A high-throughput method for quantifying alleles and haplotypes of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-1 19 kDa. Malaria Journal, 2006, 5, 31.	2.3	36
96	Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine–pyrimethamine in Mali. International Journal for Parasitology, 2010, 40, 1213-1220.	3.1	34
97	Association between the Pharmacokinetics and In Vivo Therapeutic Efficacy of Sulfadoxine-Pyrimethamine in Malawian Children. Antimicrobial Agents and Chemotherapy, 2005, 49, 3601-3606.	3.2	33
98	Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi. PLoS ONE, 2008, 3, e1578.	2.5	31
99	Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. Scientific Reports, 2018, 8, 6281.	3.3	31
100	Next Generation Sequencing to Detect Variation in the Plasmodium falciparum Circumsporozoite Protein. American Journal of Tropical Medicine and Hygiene, 2012, 86, 775-781.	1.4	30
101	A Longitudinal Trial Comparing Chloroquine as Monotherapy or in Combination with Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria. PLoS ONE, 2012, 7, e42284.	2.5	30
102	HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls. Infection and Immunity, 2005, 73, 5799-5808.	2.2	29
103	<i>Pneumocystis</i> Pneumonia in HIV-positive Adults, Malawi1. Emerging Infectious Diseases, 2007, 13, 325-328.	4.3	29
104	The interaction between HIV and malaria in Africa. Current Infectious Disease Reports, 2007, 9, 47-54.	3.0	29
105	Ordered Accumulation of Mutations Conferring Resistance to Sulfadoxine-Pyrimethamine in the Plasmodium falciparum Parasite. Journal of Infectious Diseases, 2014, 209, 130-139.	4.0	29
106	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. PLoS ONE, 2014, 9, e97398.	2.5	28
107	Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1761-1769.	1.4	28
108	Monitoring antifolate resistance in intermittent preventive therapy for malaria. Trends in Parasitology, 2013, 29, 497-504.	3.3	27

#	Article	IF	Citations
109	Observational Cohort Study of HIV-Infected African Children. Pediatric Infectious Disease Journal, 2006, 25, 623-627.	2.0	26
110	Successful Human Infection with P. falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection. PLoS ONE, 2013, 8, e68969.	2.5	26
111	Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. Journal of Infectious Diseases, 2015, 212, 694-701.	4.0	25
112	Two complement receptor one alleles have opposing associations with cerebral malaria and interact with $\hat{l}\pm\pm$ thalassaemia. ELife, 2018, 7, .	6.0	25
113	Reduced T Regulatory Cell Response during Acute Plasmodium falciparum Infection in Malian Children Co-Infected with Schistosoma haematobium. PLoS ONE, 2012, 7, e31647.	2.5	24
114	Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. Scientific Reports, 2020, 10, 3952.	3.3	24
115	Prevalence of Clinical and Subclinical Plasmodium falciparum and Plasmodium vivax Malaria in Two Remote Rural Communities on the Myanmar–China Border. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1524-1531.	1.4	24
116	A comprehensive survey of polymorphisms conferring anti-malarial resistance in Plasmodium falciparum across Pakistan. Malaria Journal, 2013, 12, 300.	2.3	23
117	Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1274-1284.	1.4	23
118	Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. MSphere, 2019, 4, .	2.9	23
119	Selection of Antifolate-Resistant Plasmodium falciparum by Sulfadoxine-Pyrimethamine Treatment and Infectivity to Anopheles Mosquitoes. American Journal of Tropical Medicine and Hygiene, 2007, 77, 438-443.	1.4	23
120	Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications. PLoS ONE, 2014, 9, e101783.	2.5	22
121	Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: Results of a Phase I randomized trial. Vaccine, 2009, 27, 2171-2176.	3.8	21
122	Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. American Journal of Tropical Medicine and Hygiene, 2007, 77, 438-43.	1.4	21
123	Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. Journal of Infectious Diseases, 2013, 208, 1514-1519.	4.0	20
124	Seroreactivity to a Large Panel of Field-Derived Plasmodium falciparum Apical Membrane Antigen 1 and Merozoite Surface Protein 1 Variants Reflects Seasonal and Lifetime Acquired Responses to Malaria. American Journal of Tropical Medicine and Hygiene, 2015, 92, 9-12.	1.4	20
125	A microarray platform and novel SNP calling algorithm to evaluate Plasmodium falciparum field samples of low DNA quantity. BMC Genomics, 2014, 15, 719.	2.8	18
126	Plasmodium falciparum field isolates from areas of repeated emergence of drug resistant malaria show no evidence of hypermutator phenotype. Infection, Genetics and Evolution, 2015, 30, 318-322.	2.3	18

#	Article	IF	Citations
127	Expression of complement and toll-like receptor pathway genes is associated with malaria severity in Mali: a pilot case control study. Malaria Journal, 2016, 15, 150.	2.3	18
128	Dose-Dependent Infectivity of Aseptic, Purified, Cryopreserved Plasmodium falciparum 7G8 Sporozoites in Malaria-Naive Adults. Journal of Infectious Diseases, 2019, 220, 1962-1966.	4.0	17
129	Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2005, 72, 267-72.	1.4	16
130	A comparison of anemia in hemoglobin C and normal hemoglobin A children with Plasmodium falciparum malaria. Acta Tropica, 2004, 90, 295-299.	2.0	15
131	Antigen-Specific B Memory Cell Responses to Plasmodium falciparum Malaria Antigens and Schistosoma haematobium Antigens in Co-Infected Malian Children. PLoS ONE, 2012, 7, e37868.	2.5	15
132	Resistance nailed. Nature, 2014, 505, 30-31.	27.8	15
133	Vaccine-Resistant Malaria. New England Journal of Medicine, 2015, 373, 2082-2083.	27.0	15
134	Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next?. Trends in Parasitology, 2001, 17, 570-571.	3.3	14
135	Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine. PLoS ONE, 2017, 12, e0173294.	2.5	14
136	Antibody Profiling by Proteome Microarray with Multiplex Isotype Detection Reveals Overlap between Human and <i>Aotus nancymaae</i> Controlled Malaria Infections. Proteomics, 2018, 18, 1700277.	2.2	14
137	Platelet-mediated clumping of Plasmodium falciparum infected erythrocytes is associated with high parasitemia but not severe clinical manifestations of malaria in African children. American Journal of Tropical Medicine and Hygiene, 2007, 77, 943-6.	1.4	14
138	Hemoglobin C Trait Provides Protection From Clinical Falciparum Malaria in Malian Children. Journal of Infectious Diseases, 2015, 212, 1778-1786.	4.0	13
139	New var reconstruction algorithm exposes high var sequence diversity in a single geographic location in Mali. Genome Medicine, 2017, 9, 30.	8.2	13
140	Combination Therapy for Malaria: Mission Accomplished?. Clinical Infectious Diseases, 2007, 44, 1075-1077.	5.8	12
141	Chloroquine-Azithromycin Combination Antimalarial Treatment Decreases Risk of Respiratory- and Gastrointestinal-Tract Infections in Malawian Children. Journal of Infectious Diseases, 2014, 210, 585-592.	4.0	12
142	A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples. Malaria Journal, 2017, 16, 343.	2.3	12
143	Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS ONE, 2018, 13, e0192850.	2.5	12
144	Differential Recognition of Terminal Extracellular Plasmodium falciparum VAR2CSA Domains by Sera from Multigravid, Malaria-Exposed Malian Women. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1190-1194.	1.4	11

#	Article	IF	CITATIONS
145	Strain-specific Plasmodium falciparum multifunctional CD4+ T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. Vaccine, 2016, 34, 2546-2555.	3.8	10
146	Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Plasmodium falciparum Reticulocyte–Binding Protein Homologue-5 in Kalifabougou, Mali. American Journal of Tropical Medicine and Hygiene, 2018, 99, 43-50.	1.4	10
147	TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial. Trials, 2016, 17, 322.	1.6	8
148	Presidential Address: Tropical Medicine in War and Peace â€. American Journal of Tropical Medicine and Hygiene, 2016, 95, 5-9.	1.4	8
149	Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. Malaria Journal, 2019, 18, 13.	2.3	8
150	Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial. Clinical Infectious Diseases, 2021, 73, 1058-1065.	5.8	8
151	Long-term Maintenance of CD4 T Cell Memory Responses to Malaria Antigens in Malian Children Coinfected with Schistosoma haematobium. Frontiers in Immunology, 2017, 8, 1995.	4.8	7
152	Selection of pfcrt K76 and pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in Mali. International Journal of Molecular Sciences, 2021, 22, 6057.	4.1	7
153	Host and Parasite Transcriptomic Changes upon Successive Plasmodium falciparum Infections in Early Childhood. MSystems, 2020, 5, .	3.8	7
154	Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls. American Journal of Tropical Medicine and Hygiene, 2006, 75, 199-204.	1.4	7
155	Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL- $\hat{l}\pm$ tag. Malaria Journal, 2019, 18, 273.	2.3	6
156	Antibody signatures of asymptomatic Plasmodium falciparum malaria infections measured from dried blood spots. Malaria Journal, 2021, 20, 378.	2.3	6
157	Artemether–Lumefantrine and Dihydroartemisinin–Piperaquine Retain High Efficacy for Treatment of Uncomplicated Plasmodium falciparum Malaria in Myanmar. American Journal of Tropical Medicine and Hygiene, 2020, 102, 598-604.	1.4	6
158	Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. Vaccine, 2020, 38, 5700-5706.	3.8	5
159	No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China–Myanmar border. Malaria Journal, 2020, 19, 334.	2.3	5
160	Malaria Exposure in Ann Township, Myanmar, as a Function of Land Cover and Land Use: Combining Satellite Earth Observations and Field Surveys. GeoHealth, 2020, 4, e2020GH000299.	4.0	5
161	RARE PLASMODIUM FALCIPARUM MEROZOITE SURFACE PROTEIN 1 19-KDA (MSP-119) HAPLOTYPES IDENTIFIED IN MALI USING HIGH-THROUGHPUT GENOTYPING METHODS. American Journal of Tropical Medicine and Hygiene, 2007, 76, 855-859.	1.4	5
162	Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. American Journal of Tropical Medicine and Hygiene, 2007, 76, 855-9.	1.4	5

#	Article	IF	CITATIONS
163	Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?. American Journal of Tropical Medicine and Hygiene, 2006, 75, 373-4.	1.4	5
164	Successful Profiling of Plasmodium falciparum <i>var</i> Gene Expression in Clinical Samples via a Custom Capture Array. MSystems, 2021, 6, e0022621.	3.8	4
165	Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens. Vaccine Journal, 2017, 24, .	3.1	3
166	Epitope-Specific Antibody Responses to a <i>Plasmodium falciparum</i> Subunit Vaccine Target in a Malaria-Endemic Population. Journal of Infectious Diseases, 2021, 223, 1943-1947.	4.0	3
167	Serologic and Cytokine Profiles of Children with Concurrent Cerebral Malaria and Severe Malarial Anemia Are Distinct from Other Subtypes of Severe Malaria. American Journal of Tropical Medicine and Hygiene, 2022, 107, 315-319.	1.4	3
168	Artemisinin resistance in Myanmar. Lancet Infectious Diseases, The, 2015, 15, 1001-1002.	9.1	2
169	Detecting geospatial patterns of Plasmodium falciparum parasite migration in Cambodia using optimized estimated effective migration surfaces. International Journal of Health Geographics, 2020, 19, 13.	2.5	2
170	High-throughput detection of eukaryotic parasites and arboviruses in mosquitoes. Biology Open, 2021, 10, .	1.2	2
171	Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation. Scientific Reports, $2021, 11, 14401$.	3.3	2
172	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. Npj Vaccines, 2021, 6, 115.	6.0	2
173	Malaria: Clinical and Epidemiological Aspects. , 0, , 633-641.		2
174	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. Microorganisms, 2022, 10, 1090.	3 . 6	2
175	The (International) American Society of Tropical Medicine and Hygiene. American Journal of Tropical Medicine and Hygiene, 2016, 95, 980-982.	1.4	1
176	The Jeremiah Metzger lecture: new additions to the toolbox for global malaria eradication. Transactions of the American Clinical and Climatological Association, 2014, 125, 271-80.	0.5	1
177	Reply to Muula. Journal of Infectious Diseases, 2006, 194, 1188-1189.	4.0	0
178	Genomic Epidemiology of Antimalarial Drug Resistance in Plasmodium falciparum in Southern China. Frontiers in Cellular and Infection Microbiology, 2020, 10, 610985.	3.9	0
179	Malaria Genomics and the Developing World. Advances in Microbial Ecology, 2012, , 117-130.	0.1	0
180	Malaria Vaccines. , 2013, , 171-197.		0

#	Article	IF	CITATIONS
181	Professor Ogobara K. Doumbo (1956–June 9, 2018). American Journal of Tropical Medicine and Hygiene, 2018, 99, 1118-1119.	1.4	O